Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company developing orexin receptor 2 (OX2R) agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. This role is a temporary position with the potential to convert to a permanent role, accountable for study delivery, including operational strategy, timelines, budget, quality, vendor oversight, risk management, and inspection readiness.